◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Suzhou Ribo Life Science Co (6938) Financial History

Name: Suzhou Ribo Life Science Co (6938) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Suzhou Ribo Life Science Co (6938) operates in the Biotechnology industry and is headquartered in Kunshan, China with about 407 employees. Its market capitalization is roughly CNY 9 billion. In the fiscal year ended 2025-12-31, 6938 reported CNY 148M in revenue and (CNY 278M) in net income.

Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally.

Interactive charts & full statements →

6938 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31
Total Revenue	CNY 148M	CNY 143M	CNY 0M
Gross Profit	CNY 135M	CNY 131M	CNY 0M
Operating Income (EBIT)	(CNY 251M)	(CNY 226M)	(CNY 372M)
Net Income	(CNY 278M)	(CNY 270M)	(CNY 428M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6938 Free Cash Flow History

6938 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31
Total Assets	CNY 840M	CNY 651M	CNY 716M
Total Liabilities	CNY 813M	CNY 762M	CNY 600M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6938 viewer.

Other Companies in Biotechnology

6872 · TENNOR THERAP-B — $10 billion
NUVL · Nuvalent Inc — $10 billion
1779 · LONGBIO-B — $10 billion
ABVX · ABIVAX Société Anonyme — $9 billion
2171 · CARsgen Therapeutics Holdings Limited — $9 billion
2616 · CStone Pharmaceuticals — $8 billion
2256 · Abbisko Cayman Limited — $8 billion
9966 · Alphamab Oncology — $8 billion

← 6936 All “0-9” companies 6939 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.